Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Med Chem ; 64(22): 16675-16686, 2021 11 25.
Artículo en Inglés | MEDLINE | ID: mdl-34761949

RESUMEN

Half-sandwich complexes of iridium(III) are currently being developed as anticancer drug candidates. In this context, we introduce IrBDP for which the C^N chelating phenyloxazoline ligand carries a fluorescent and lipophilic BODIPY reporter group, designed for intracellular tracking and hydrophobic compartment tropism. High-resolution analysis of cells cultured with IrBDP showed that it quickly permeates the plasma membrane and accumulates in the mitochondria and endoplasmic reticulum (ER), generating ER stress, dispersal of the Golgi apparatus, cell proliferation arrest and apoptotic cell death. Moreover, IrBDP forms fluorescent adducts with a subset of amino acids, namely histidine and cysteine, via coordination of N or S donor atoms of their side chains. Consistently, in vivo formation of covalent adducts with specific proteins is demonstrated, providing a molecular basis for the observed cytotoxicity and cellular response. Collectively, these results provide a new entry to the development of half-sandwich iridium-based anticancer drugs.


Asunto(s)
Antineoplásicos/farmacología , Compuestos de Boro/química , Estrés del Retículo Endoplásmico , Iridio/química , Proteínas/química , Células HeLa , Humanos
2.
ChemMedChem ; 14(19): 1717-1726, 2019 10 04.
Artículo en Inglés | MEDLINE | ID: mdl-31483560

RESUMEN

The ferrocenyl diphenol complexes 1,1-bis(4'-hydroxyphenyl)-2-ferrocenyl-but-1-ene (1) and 1,2-bis(4'-hydroxyphenyl)-1-ferrocenyl-but-1-ene [(Z)-2], which differ by the relative position of the two phenolic substituents, display dramatically different antiproliferative activities on cancer cells (1 is far more cytotoxic than 2). In this study, our goal was to discover the origin of this difference by comparing their reactivity and biological behaviour. In terms of common behaviour, we found that 1 and 2 are both efficient inhibitors of thioredoxin reductase (TrxR) in vitro after oxidation by a horseradish peroxidase/H2 O2 system. However, as 1 is only a moderate inhibitor of TrxR in MDA-MB-231 cells, TrxR is probably not the major target responsible for the cytotoxicity of 1. In terms of differences, we noted that 1 induced a significant redox imbalance characterised by lipid peroxidation and thiol oxidation, and a moderate decrease of the mitochondrial membrane potential in breast cancer cells, whereas 2 has almost no effect. These results underline the importance of the trans configuration in the ferrocenyl-double bond-phenol motif, which is present in 1 but is cis in (Z)-2.


Asunto(s)
Antineoplásicos/química , Complejos de Coordinación/química , Inhibidores Enzimáticos/química , Compuestos Ferrosos/química , Reductasa de Tiorredoxina-Disulfuro/antagonistas & inhibidores , Antineoplásicos/farmacología , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Complejos de Coordinación/farmacología , Inhibidores Enzimáticos/farmacología , Humanos , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Oxidación-Reducción
3.
J Exp Clin Cancer Res ; 38(1): 306, 2019 Jul 12.
Artículo en Inglés | MEDLINE | ID: mdl-31299997

RESUMEN

BACKGROUND: HER2-overexpressing metastatic breast cancers are challenging practice in oncology when they become resistant to anti-HER2 therapies such as trastuzumab. In these clinical situations, HER2-overexpression persists in metastatic localizations, and can thus be used for active targeting using innovative therapeutic approaches. Functionalized gold nanoparticles with anti-HER2 antibody can be stimulated by near-infrared light to induce hyperthermia. METHODS: Here, hybrid anti-HER2 gold nanoshells were engineered for photothermal therapy to overcome trastuzumab resistance in HER2-overexpressing breast cancer xenografts. RESULTS: When gold nanoshells were administered in HER2-tumor xenografts, no toxicity was observed. A detailed pharmacokinetic study showed a time-dependent accumulation of gold nanoshells within the tumors, significantly greater with functionalized gold nanoshells at 72 h. This enabled us to optimize the treatment protocol and irradiate the mice when the anti-HER2 gold nanoshells had accumulated most in the tumors. After weekly injections of anti-HER2 gold nanoshells, and repeated irradiations with a femtosecond-pulsed laser over four weeks, tumor growth was significantly inhibited. Detailed tissue microscopic analyses showed that the tumor growth inhibition was due to an anti-angiogenic effect, coherent with a preferential distribution of the nanoshells in tumor microvessels. We also showed a direct tumor cell effect with apoptosis and inhibition of proliferation, coherent with an immune-mediated targeting of tumor cells by anti-HER2 nanoshells. CONCLUSION: This preclinical study thus supports the use of anti-HER2 gold nanoshells and photothermal therapy to overcome trastuzumab resistance in HER2-overexpressing breast cancer.


Asunto(s)
Antineoplásicos Inmunológicos/administración & dosificación , Portadores de Fármacos , Resistencia a Antineoplásicos/genética , Oro , Rayos Láser , Nanocáscaras , Trastuzumab/administración & dosificación , Animales , Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/genética , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Modelos Animales de Enfermedad , Femenino , Dosificación de Gen , Regulación de la Expresión Génica , Oro/química , Humanos , Imagen por Resonancia Magnética , Ratones , Nanocáscaras/química , Neovascularización Patológica/tratamiento farmacológico , Fototerapia , Receptor ErbB-2/genética , Dióxido de Silicio/química , Ensayos Antitumor por Modelo de Xenoinjerto
4.
ACS Nano ; 9(8): 7925-39, 2015 Aug 25.
Artículo en Inglés | MEDLINE | ID: mdl-26168364

RESUMEN

Safe implementation of nanotechnology and nanomedicine requires an in-depth understanding of the life cycle of nanoparticles in the body. Here, we investigate the long-term fate of gold/iron oxide heterostructures after intravenous injection in mice. We show these heterostructures degrade in vivo and that the magnetic and optical properties change during the degradation process. These particles eventually eliminate from the body. The comparison of two different coating shells for heterostructures, amphiphilic polymer or polyethylene glycol, reveals the long lasting impact of initial surface properties on the nanocrystal degradability and on the kinetics of elimination of magnetic iron and gold from liver and spleen. Modulation of nanoparticles reactivity to the biological environment by the choice of materials and surface functionalization may provide new directions in the design of multifunctional nanomedicines with predictable fate.


Asunto(s)
Envejecimiento/fisiología , Materiales Biocompatibles Revestidos/farmacocinética , Portadores de Fármacos/farmacocinética , Compuestos Férricos/farmacocinética , Oro/farmacocinética , Nanopartículas de Magnetita/análisis , Alquenos/química , Animales , Materiales Biocompatibles Revestidos/química , Portadores de Fármacos/química , Compuestos Férricos/química , Oro/química , Inyecciones Intravenosas , Hígado/metabolismo , Hígado/ultraestructura , Nanopartículas de Magnetita/química , Nanopartículas de Magnetita/ultraestructura , Anhídridos Maleicos/química , Ratones , Ratones Endogámicos C57BL , Nanomedicina/instrumentación , Nanomedicina/métodos , Polietilenglicoles/química , Polímeros/química , Bazo/metabolismo , Bazo/ultraestructura , Electricidad Estática , Propiedades de Superficie
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA